HIV

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Yahoo/Reuters
GSK
Gilead Sciences
HIV
AIDS
Dolutegravir
lamivudine
Biktarvy
Flag link:
ViiV Healthcare reports positive results for late-stage HIV trials
ViiV Healthcare reports positive results for late-stage HIV trials
Marketwatch
ViiV Healthcare
GSK
Pfizer
Shionogi
HIV
clinical trials
Dolutegravir
lamivudine
Flag link:
New HIV vaccine test shows promise
New HIV vaccine test shows promise
Axios
HIV
vaccines
Flag link:
Gilead, Hookipa pen hepatitis B, HIV research collaboration
Gilead, Hookipa pen hepatitis B, HIV research collaboration
Fierce Biotech
Gilead Sciences
Hookipa
hepatitis B
HIV
vaccines
drug development
Flag link:
ViiV Receives EU Authorization for Juluca, the First 2-Drug, Once-Daily Pill for HIV
ViiV Receives EU Authorization for Juluca, the First 2-Drug, Once-Daily Pill for HIV
CP Wire
ViiV Healthcare
Juluca
Europe
HIV
Flag link:
ViiV Receives EU Authorization for Juluca, the First 2-Drug, Once-Daily Pill for HIV
ViiV Healthcare
HIV
Juluca
Flag link:
Regulators flag possible birth defect link to GSK's HIV drug
Regulators flag possible birth defect link to GSK's HIV drug
Yahoo/Reuters
GSK
HIV
Dolutegravir
birth defects
EMA
FDA
Flag link:
HIV Patients File Class Action and Personal Injury Lawsuits for California Patients Against Gilead
HIV Patients File Class Action and Personal Injury Lawsuits for California Patients Against Gilead
CP Wire
Gilead Sciences
HIV
patients
TDF
TAF
California
Flag link:
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
Fierce Pharma
GSK
HIV
Biktarvy
Gilead Sciences
Triumeq
Tivicay
Flag link:
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
CP Wire
Gilead Sciences
Biktarvy
HIV
Flag link:
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
Gilead Sciences
Biktarvy
HIV
Flag link:
Look at our new launches, GSK urges, as its respiratory woes steal the limelight
Look at our new launches, GSK urges, as its respiratory woes steal the limelight
Fierce Pharma
GSK
earnings
HIV
Shingrix
Flag link:
Gene editing shows promise in combating HIV reservoirs
Gene editing shows promise in combating HIV reservoirs
Fierce Biotech
gene editing
HIV
Flag link:
Gilead: Did Biktarvy Kill The Sell Thesis?
Gilead: Did Biktarvy Kill The Sell Thesis?
Seeking Alpha
Gilead Sciences
Biktarvy
HIV
Kite Pharma
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
GSK's two-drug HIV regimen wins European panel approval
GSK's two-drug HIV regimen wins European panel approval
Reuters
GSK
HIV
Europe
CHMP
Juluca
Flag link:
Gilead Sciences' $14 Billion-Per-Year Threat
Gilead Sciences' $14 Billion-Per-Year Threat
Motley Fool
Gilead Sciences
GS-9620
GS-9722
HIV
Flag link:
Is Gilead Sciences Trying to Put Itself Out of Business?
Is Gilead Sciences Trying to Put Itself Out of Business?
Motley Fool
Gilead Sciences
hepatitis C
HIV
GS-9620
PGT121
Flag link:
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Endpoints
HIV
Gilead Sciences
R&D
Flag link:
How Huge Is the Latest HIV Drug Approval for Gilead Sciences?
How Huge Is the Latest HIV Drug Approval for Gilead Sciences?
Motley Fool
Gilead Sciences
HIV
FDA
Biktarvy
Flag link:

Pages